Eli Lilly reports fiscal Q3 2025 results: revenue $17.60B, up 54% from a year earlier

Eli Lilly filed a Form 8-K with the SEC on Oct 30, 2025, 7:03 AM ET, reporting an event dated Oct 30, 2025. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q3 2025 (quarter ended Sep 30, 2025); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $17.60B (+53.9% from $11.44B a year earlier)
• Net income: $5.58B (+475.3% from $970.3M a year earlier)
• Diluted EPS: $6.21 (+480.4% from $1.07 a year earlier)
• Form 8-K accepted by EDGAR Oct 30, 2025, 7:03 AM ET
• Accession number 0000059478-25-000251

SEC filing 8-K · accession 0000059478-25-000251 · sec.gov ↗